Enveric Biosciences (NASDAQ:ENVB) Announces Quarterly Earnings Results

Enveric Biosciences (NASDAQ:ENVB) posted its earnings results on Friday. The company reported ($1.08) earnings per share for the quarter, FiscalAI reports.

Enveric Biosciences Stock Performance

Shares of NASDAQ:ENVB traded down $0.04 during midday trading on Friday, hitting $2.25. The company’s stock had a trading volume of 134,720 shares, compared to its average volume of 11,244,770. The stock has a market capitalization of $4.48 million, a price-to-earnings ratio of -0.06 and a beta of 1.24. The stock’s 50 day simple moving average is $2.55 and its 200 day simple moving average is $3.79. Enveric Biosciences has a fifty-two week low of $1.71 and a fifty-two week high of $17.64.

Institutional Investors Weigh In On Enveric Biosciences

An institutional investor recently raised its position in Enveric Biosciences stock. AdvisorShares Investments LLC raised its stake in shares of Enveric Biosciences, Inc. (NASDAQ:ENVB) by 96.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 203,679 shares of the company’s stock after purchasing an additional 100,000 shares during the quarter. AdvisorShares Investments LLC owned 39.32% of Enveric Biosciences worth $130,000 as of its most recent filing with the Securities and Exchange Commission. 13.82% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Enveric Biosciences Company Profile

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.